Citigroup’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.08M Buy
29,400
+2,400
+9% +$87K ﹤0.01% 3260
2026
Q2
$956K Hold
27,000
– – ﹤0.01% 3473
2026
Q1
$748K Sell
27,000
-173,000
-87% -$4.44M ﹤0.01% 3303
2025
Q4
$4.34M Hold
200,000
– – ﹤0.01% 2119
2025
Q3
$3.03M Buy
+200,000
New +$2.48M ﹤0.01% 2344
2024
Q2
– Sell
-35,900
Closed -$378K – 5746
2024
Q1
$378K Sell
35,900
-12,100
-25% -$130K ﹤0.01% 3723
2023
Q4
$539K Buy
+48,000
New +$468K ﹤0.01% 3353

Other funds holding ROIV

Citigroup's ROIV Position: Q3 2026 in Review

Citigroup increased its Roivant Sciences (ROIV) stake by 25% in Q3 2026, buying an estimated $20M and bringing the position to 2,777,582 shares worth $102M. The position accounts for 0.03% of the portfolio, ranked #497.

Citigroup first reported a position in ROIV in Q4 2021 and has held it in 20 quarters since. 181 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • Citigroup held 2,777,582 shares of Roivant Sciences worth $102M as of Q3 2026.
  • Citigroup bought 552,392 Roivant Sciences shares in Q3 2026, an estimated $20M.
  • Roivant Sciences made up 0.03% of Citigroup's portfolio in Q3 2026, its #497 holding.
  • Citigroup first reported a position in Roivant Sciences in Q4 2021 and has held it in 20 quarters since.
  • 181 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.